Dr. Satish A. Shah, MD

Dr. Shah practices at Satish a Shah MD in Gettysburg, Pennsylvania.

Dr. Shah's NPI, 1487679593, was assigned on July 12, 2006. Dr. Shah holds Pennsylvania license MD039646L.

Dr. Shah's primary practice is Satish a Shah MD, at 20 Expedition Trl, Gettysburg, PA 17325 in Adams County. The practice phone is (717) 334-4033.

Dr. Shah's primary practice is Satish a Shah MD in Gettysburg, Pennsylvania. Dr. Shah is also affiliated with WellSpan Gettysburg Hospital. The medical group on file is Chesapeake Urology Associates. Dmand AI also links Dr. Shah to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shah practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Shah's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Shah's licenses on file in 2 states: Pennsylvania and Maryland.

CMS data shows 41,107 Medicare services from Dr. Shah across 39 procedure codes in 2024, for 523 Medicare patients. Medicare paid $531,148 for them.

CMS counts 523 Medicare patients who saw Dr. Shah in 2024. The largest group is 75 to 84, with 210 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shah's median patient age at 71, with 55% women.

In 2024, Dr. Shah wrote 1,923 Medicare Part D claims for 226 patients. CMS names the drug for 1,601 of them, across 45 drugs with 11 or more claims each, at $7,278,320 in total drug cost. In 2023, CMS named 876 claims across 31 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Shah for performance year 2024, reported individually. Dr. Shah accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 3 papers to Dr. Shah, published from 2019 to 2022. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols. Dr. Shah's most frequent co-authors are Nabil Adra, MD, Angela R. Bradbury, MD and George Winther Cole, MD.

Dmand AI links Dr. Shah to 14 clinical trials, 4 of them phase 3 studies. 5 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Prostatic Neoplasms. ImmunityBio, Inc. sponsors the most, 2. Open Payments lists research payments to Dr. Shah that name 4 trials.

CMS Open Payments shows 510 general payments to Dr. Shah from 86 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 76% of the total. AstraZeneca Pharmaceuticals LP paid the most, $114,066. It also lists 55 research payments totaling $387,565 from 2016 to 2023, naming 4 clinical trials.